In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Oncolytics Biotech (ONCY – Research Report), with a price target of $3.00. The company’s shares opened today at $1.92.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Immutep, and Actinium Pharmaceuticals. According to TipRanks, McCarthy has an average return of -39.6% and a 14.32% success rate on recommended stocks.
Oncolytics Biotech has an analyst consensus of Strong Buy, with a price target consensus of $7.50, implying a 290.63% upside from current levels. In a report released on November 7, RBC Capital also maintained a Buy rating on the stock with a C$6.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.08 and a one-year low of $0.80. Currently, Oncolytics Biotech has an average volume of 98.75K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Read More on ONCY: